Regencell Bioscience Holdings (Regencell Bioscience Holdings) EPS (Diluted) : $-0.45 (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings EPS (Diluted)?

Regencell Bioscience Holdings's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was $-0.20. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

Regencell Bioscience Holdings's EPS (Basic) for the six months ended in Jun. 2023 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

Regencell Bioscience Holdings's EPS without NRI for the six months ended in Jun. 2023 was $-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

During the past 3 years, the average EPS without NRIGrowth Rate was -91.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Regencell Bioscience Holdings's highest 3-Year average EPS without NRI Growth Rate was -91.60% per year. The lowest was -165.50% per year. And the median was -128.55% per year.

Regencell Bioscience Holdings EPS (Diluted) Historical Data

The historical data trend for Regencell Bioscience Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings EPS (Diluted) Chart

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

EPS (Diluted)

-0.03

-0.06

-0.11

-0.58

-0.45

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EPS (Diluted)	Get a 7-Day Free Trial				-0.08	-0.29	-0.29	-0.25	-0.20

Competitive Comparison of Regencell Bioscience Holdings's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's PE Ratio falls into.

Regencell Bioscience Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Regencell Bioscience Holdings's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-5.871	-	0)	/	13.013
	=	-0.45

Regencell Bioscience Holdings's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2.644	-	0)	/	13.013
	=	-0.20

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.45

Regencell Bioscience Holdings (NAS:RGC) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Regencell Bioscience Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.